BTK and B-cell chronic lymphocytic leukemia: Since both the B-cell receptor and WNT/PCP pathways regulate the migration and proliferation of CLL cells, and the BTK inhibitor ibrutinib can only block signals from the B-cell receptor, it was reasonable to therapeutically pair ibrutinib with anti-ROR1 mAb.